Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/P7O INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: December 28 2001 (use as many sheets as necessa

of

Sheet

3

.\	Complete if Known	贾	77)
Application Number	09/851,422	主。	Π
Jiling Date	05/09/2001	\mathcal{G}	
First Named Inventor	Xianxhang YU	7.	The s
Group Art Unit	1646	F	
Examiner Name	Unassigned	79	<u> </u>
Attorney Docket Number	035879-0122	66	3 11
		~	

				U.S. PATENT DOCUMENTS	S	900	
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
m·4	A1	6,255,282	B1	Jaynes	07/03/2001		

	FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.1	Cite	Cite Foreign Patent Docu			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant		
	No.1	Office ³ Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶		
PM)	A2	PCT 97/33908		Rivett et al.	09/18/1997				
TV- U									

				1.1 40-104			-		

							\perp		
				_					

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Cit Initials* No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
M	A3 /	BLONDELLE et al., "Hemolytic and Antimicrobial Activities of the Twenty-Four Individual Omission Analogues of Melittin," <i>Biochemistry</i> , 1991, pp. 4671-4678, Vol. 30, American Chemical Society.	
١	A4 √	DEMPSEY et al., "Contributioon of Proline-14 to the Structure and Actions of Melittin," FEBS Letters, 1991, pp. 240-244, Vol. 281, No. 1,2, Elsevier Science Publishers B.V.	
	A5 ,	LEIPPE et al., "Cytolytic and Antibacterial Activity of Synthetic Peptides Derived from amoebapore, the Pore-Forming Peptide of Entamoeba Histolytica," Proc. Natl. Acad. Sci. USA, 1994, pp. 2602-2606, Vol. 91.	
	A6 /	ANDRÄ et al., "Shortened Amoebapore Analogs with Enhanced Antibacterial and Cytolytic Activity," FEBS Letters, 1996, pp. 96-100, Vol. 385, Federation of European Biochemical Societies.	
7	A7 V	SHAI et al., "Diastereomers of Cytolysins, a Novel Class of Potent Antibacterial Peptides," <i>Journal Biological Chemistry</i> , 1996, pp. 7305-7308, Vol. 271 No. 13, The American Society for Biochemistry and Molecular Biology, Inc.	

Examiner	Ma Torody S	Date Considered	5-6-03
Signature	/ Wasan _	Considered	<u> </u>

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

^{*}EXAMINER: Initial if reference considered/whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no passpread to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE 1 8 2002
STATEMENT BY APPLICANT

Date Submitted: December 28 2001

(use as many sheets as necessary)

2 of 3

Sheet

1	Complete if Known	A_{λ}
Application Number	09/851,422	*
Filing Date	05/09/2001	- CX.
First Named Inventor	Xianxhang YU	JAN SIL
Group Art Unit	1646 CX	70 72
Examiner Name	Unassigned	CENO 320
Attorney Docket Number	035879-0122	TED VOZ
	, , , , , , , , , , , , , , , , , , , ,	160

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS)
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
My	A8/	WERKMEISTER et al., "The Effect of Sequence Variations and Structure on the Cytolytic Activity of Melittin Peptides," <i>Biochimica et Biophysica Acta</i> , 1993, pp. 50-54, Vol. 1157, Elsevier Science Publishers B.V.	
1	A9 🗸	LEIPPE et al., "Pore-Forming Peptide of Pathogenic <i>Entamoeba Histolytica</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 1991, pp. 7659-7663, Vol. 88.	
	A10,	HOROSZEWICZ et al., "LNCaP Model of Human Prostatic Carcinoma ¹ ," <i>Cancer Research</i> , 1983, pp. 1809-1818, Vol. 43, No. 4, Dept. of Biological Resources, Roswell Park Memorial Inst. Buffalo, New York.	
	A11	PINTO et al., "Prostate Specific Membrane Antigen, a Unique Glutamate Carboxypeptidase: A Review of Recent Findings," <i>The Prostate Journal</i> , 1999, pp. 15-26, Vol. 1, No. 1, Blackwell Science, Inc.	
		/LOPES et al., "Immunohistochemical and Pharmacokinetic Characterization of the Site-Specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody," <i>Cancer Research</i> , 1990, pp. 6423-6429, Vol. 50, American Association for Cancer Research.	
	A13 _v	TROYER et al., "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids," <i>Int. J. Cancer</i> , 1995, pp. 552-558, Vol. 62, Wiley-Liss, Inc.	
	A14 ,	WALLRAPP et al., "A Novel Transmembrane Serine Protease (TMPRSS3) Overexpressed in Pancreatice Cancer ^{1,2} ," Cancer Research, 2000, pp. 2602-2606, Vol. 60, No. 10, American Association for Cancer Research.	
	A15/	WRIGHT et al., "Expression of Prostate-Specific membrane Antigen in Normal, Benign, and Malignant Prostate Tissues," <i>Urol. Oncol.</i> , 1995, pp. 18-28, Vol. 1, Elsevier Science Inc., New York.	
	A16,	PRAUSNITZ et al., "Electroporation of Mammalian Skin: A Mechanism to Enhance Transdermal Drug Delivery", Proc. Natl. Acad. Sci. USA, 1993, pp. 10504-10508, Vol. 90, No. 22, Medical Sciences, NIH	
	A17,	WALLACE et al., "Stand and Deliver: Getting Peptide Drugs into the Body", Science, 1993, pp. 912-913, Vol. 260, American Association for the Advancement of Science	
	A18/	ANDREU et al., "Solid-Phase Synthesis of Cecropin A and Related Peptides", Proc. Natl. Acad. Sci. USA, 1983, pp. 6475-6479, Vol. 80, No. 21, Biochemistry, Biological Science	
	A19	ANDREU et al., "N-Terminal Analogues of Cecropin A: Synthesis, Antibacterial Activity, and Confromational Properties", Biochemistry, 1985, pp. 1683-1688, Vol. 24, No. 7, American Chemical Society	
	A20,	FINK et al., "Design, Synthesis and Antibacterial Activity of Cecropin-Like Model Peptides", Int. J. Peptide Protein Res., 1989, pp. 412-421, Vol. 33, No. 6, The Rockefeller University, New York, New York	
D	A21	FINK et al., "The Chemical Synthesis of Cecropin D and an Analog with Enhanced Antibacterial Activity", J. of Biological Chemistry, 1989, pp. 6260-6267, Vol. 264, No. 11, American Society for Biochemistry and Molecular Biology, Inc. Rockefeller University, New York	

Examiner Signature	M	isodup	Date Considered	4-6-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT JAN
Date Submitted: December 28 2001
(use as many sheets as necessar)

RADE TRADE

Sheet

	Complete if Known	CCFILE
Application Number	09/851,422	
Application Number Ħiling Date	05/09/2001	JAN 2 2
First Named Inventor	Xianxhang YU /EC	2002
Group Art Unit	1646	UENTED
Examiner Name	Unassigned	160000
Attorney Docket Number	035879-0122	-00/2900

· ·	•	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
my	A22	ARGIOLAS et al., "Bombolitins, a New Class of Mast Cell Degranulating Peptides from the Venom of the Bumblebee Megabombus Pennsylvanicus", J. of Biological Chemistry, 1985, pp. 1437-1444, Vol. 260, No. 3, American Society of Biological Chemists, Inc.	
1	A23	YOUNG et al., "Characterization of a Member Pore-Forming Protein From Entamoeba Histolytica", J. Exp. Med. 1982, pp. 1677-1690, Vol. 156, No. 6, The Rockefeller University Press	
	A24 /	LYNCH et al., "An Ion-Channel Forming Protein Produced by Entamoeba Histolytica", The EMBO Journal, 1982, pp. 801-804, Vol. 1, No. 7, IRL Press Limited, Oxford, England	
	A25	YOUNG et al., "Molecular Mechanisms of Cytotoxicity Mediated by Entamoeba Histolytica: Characterization of a Pore-Forming Protein (PFP)", J. of Cellular Biochemistry, 1985, pp. 299-308, Vol. 29 No. 4, Alan R. Liss, Inc.	
	A26	ROSENBERG et al., "Isolation, Characterization and Partial Purification of a Transferable Membrane Channel (Amoebapore) Produced by Entamoeba Histolytica", Molecular and Biochemical Parasitology, 1989, pp. 237-248, Vol. 33, No. 3, Elsevier Science Publishers B.V.	-
	A27	JANSSON et al., "Coding of Hemolysins Within the Ribosomal RNA Repeat on a Plasmid in Entamoeba Histolytica", Science, 1994, pp. 11440-1443, Vol. 263, American Association for the Advancement of Science	
U	A28 ,	WOODLE e tal., "Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat", Pharmaceutical Research, 1992, Vol. 9, No. 2, Plenum Press, New York	

Examiner Signature	Missoh	y	Date Considered	5-6-03

*EXAMINER: Initial if reference considered, whitether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Page 1 of 1

Form PTO A	×49	U.S. DEPARTME	NT OF COMMERCE	SERIAL N			O.	
(MODIFIED)	10		ADEMARK OFFICE			09/	851,422	2
(MODII IED)			. — — — <u>-</u> ./, д д д .	APPLICANT				
INFO	RMATI	ON DISCLOSURE	CITATION		ianxhang YU	, et al.		_
				FILING DATE GROUP ART U			TUNIT	
	(Use se	veral sheets if nece	ssarv)	05/09/2	001		1646	
	1000 00							
			U.S. PATE	NT DOCUMENTS				
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	1	DATE F PRIATE
						BEC	ŒIV	/ED
_						MAR	0 1 20	JUZ
						TECH CEN	ITER 16)0/2 9 00
						<u></u>	L	
			FOREIGN PA	TENT DOCUMENTS				
	REF	DOCUMENT	DATE	COUNTRY	CLASS	SUB-		LATION
	KEF	NUMBER				CLASS	YES	NO
		OTHER DOCU	MENTS (Including	Author, Title, Date, Pe	ertinent Pages,	Etc.)		
		CH. NAGARJUN R	AO et al "Role of ar	nino groups in the biolog	ical activity of c	vtotoxin-3 fro	m indian o	obra
my	A1. √	venon," Recent Ad	v. Toxinol. Res., (199	92), 1:514-520 (XP0010 graph 3 – page 518, par	31413); summar	y page 514, la		
				of Pseudomonas exoto				
	A2 /		127 (XP001031414);	ugated to an erythroid co summary page 124, left				
				lification of amino group				
	A3 🗸		Biochemistry and Mo oh 1 – page 183, par	olecular Biology Internati agraph 1 summary.	ional, (1993) 31(1):175-184 (X	(P001031	369)
	A4			ity and action on the sui 765 (XP001031342).	face tension of	aequeous sol	utions of s	synthetic
<u> </u>				papore analogs with enh				
7)	A 5	FEBS Letters (199 100, right hand col		2182888) abstract, page	97, right-hand	column, parag	graph 2	page
	. 							
EXAMINER				DATE CONSIDE	RED			
ł	mi	Look of	•	I	5-6-0	7		
	100						DED 600). Draw
				ther or not citation indicated in the desired in th				
		ion to applicant.	. Join Jimanoo an			-r,o		